PKG blockers DT-2 and DT-3 inhibit ROS generation triggered by bradykinin and acetylcholine in isolated cardiomyocytes, but fail to reach myocytes in whole heart models.
No takes yet. Share an insight, caveat, or question.
PKG inhibition curbs ROS in isolated cardiomyocytes; whole-heart delivery and efficacy remain unproven, warranting targeted delivery studies.
Krieg et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: